2-[6-(cyclopropylmethoxy)pyridin-3-yl]-N-(4-piperazin-1-ylpyridin-3-yl)pyrimidine-4-carboxamide | 1107625-26-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[6-(cyclopropylmethoxy)pyridin-3-yl]-N-(4-piperazin-1-ylpyridin-3-yl)pyrimidine-4-carboxamide
• CAS: 1107625-26-2
• 化学式: C₂₃H₂₅N₇O₂
• 分子量: 431.497
• InChiKey: KEQYNUVAMWPLEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS<br/>[FR] UTILISATION DE DÉRIVÉS 2-(PYRIDINE-3-YL)-PYRIMIDINE EN TANT QU'INHIBITEURS DE RET
  申请人：BLUEPRINT MEDICINES CORP

  公开号：WO2016127074A1

  公开（公告）日：2016-08-11

  Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

  本文描述了抑制野生型RET及其耐药突变体的化合物，包括这些化合物的药物组合物，以及使用这些化合物和组合物的方法。
• HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Reddy Panduranga Adulla P.

  公开号：US20100286135A1

  公开（公告）日：2010-11-11

  The present invention relates to novel heterocyclic amide compounds of Formula I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease.

  本发明涉及公式I的新异环酰胺化合物，如本文所述或其药学上可接受的盐、溶剂化物、酯、前药或立体异构体。还公开了包含该化合物的组合物，并且公开了使用该化合物治疗或预防增殖性疾病、抗增殖性障碍、炎症、关节炎、神经或神经退行性疾病、心血管疾病、脱发、神经元疾病、缺血性损伤、病毒性疾病或真菌病的方法。
• 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
  申请人：BLUEPRINT MEDICINES CORPORATION

  公开号：US10202365B2

  公开（公告）日：2019-02-12

  Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g., for treating a condition mediated by aberrant RET activity

  本文描述了抑制野生型 RET 及其抗性突变体的化合物（如式 (I) 化合物及其药学上可接受的盐）、包括此类化合物的药物组合物以及使用此类化合物和组合物的方法，例如，用于治疗由异常 RET 活性介导的疾病的方法。
• 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS
  申请人：BLUEPRINT MEDICINES CORPORATION

  公开号：US20180022731A1

  公开（公告）日：2018-01-25

  Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
• US8293747B2
  申请人：——

  公开号：US8293747B2

  公开（公告）日：2012-10-23